| 33.1114 -0.681 (-2.01%) | 06-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 39.55 |
1-year : | 40.36 |
| Resists | First : | 33.86 |
Second : | 34.56 |
| Pivot price | 33.88 |
|||
| Supports | First : | 32.74 |
Second : | 27.23 |
| MAs | MA(5) : | 33.98 |
MA(20) : | 33.79 |
| MA(100) : | 34.54 |
MA(250) : | 32.37  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 45.7 |
D(3) : | 71.1 |
| RSI | RSI(14): 40.6 |
|||
| 52-week | High : | 36.64 | Low : | 26.86 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HRTS ] has closed above bottom band by 2.5%. Bollinger Bands are 8.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.59 - 33.86 | 33.86 - 34.04 |
| Low: | 32.52 - 32.82 | 32.82 - 33.03 |
| Close: | 32.72 - 33.18 | 33.18 - 33.5 |
The Tema Heart & Health ETF (HRTS) seeks to invest in companies that potentially stand to benefit from further advances in biotechnology and healthcare, specifically companies involved in cardiology, metabolic diseases and weight loss therapies.
Fri, 29 May 2026
Behavioral Patterns of HRTS and Institutional Flows - Stock Traders Daily
Wed, 11 Jun 2025
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - The Daily Upside
Wed, 12 Feb 2025
New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype - Wealth Management
Tue, 29 Oct 2024
The 5 Best Biotech ETFs of 2024 - TradingView
Thu, 30 May 2024
Investing in the diabesity epidemic: a breakthrough moment - CMC Markets
Fri, 24 Nov 2023
HRTS Stock Fund Price and Chart — NASDAQ:HRTS - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|